Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Feb 28;343(2):156-60.
doi: 10.1016/j.canlet.2013.09.038. Epub 2013 Nov 13.

Targeted therapy in metastatic renal carcinoma

Jane Mattei  1 , Rodrigo Donalisio da Silva  1 , David Sehrt  1 , Wilson R Molina  1 , Fernando J Kim  2
Affiliations
Review

Targeted therapy in metastatic renal carcinoma

Jane Mattei et al. Cancer Lett. .

Abstract

Background: Advanced renal cell carcinoma is one of the most treatment-resistant malignancies to conventional cytotoxic chemotherapy. The development of new targeted therapy was result of understanding biological pathways underlying renal cell carcinoma. Our objective is to provide an overview of current therapies in metastatic renal cell carcinoma.

Methods: MEDLINE/PUBMED was queried in December 2012 to identify abstracts, original and review articles. The research was conducted using the following words: "metastatic renal cell carcinoma" and "target therapy". Phase II and Phase III clinical trials were included followed FDA approval. Total of 40 studies were eligible for review.

Conclusion: The result of this review shows benefit of these target drugs in tumor burden, increase progression-free and overall survival and improvement the quality of life compared with previous toxic immunotherapy, although complete response remains rare.

Keywords: Adjuvant treatment; Metastatic disease; Renal cell carcinoma; Renal tumor; Target therapy.

PubMed Disclaimer

Publication types

LinkOut - more resources